Does Kaiser Permanente Cover Forteo (Teriparatide)?

What Is Forteo and Why Does It Require Special Coverage Approval?

Forteo is a recombinant form of human parathyroid hormone (PTH 1-34) that actually builds new bone rather than simply slowing bone loss. That mechanism sets it apart from bisphosphonates such as alendronate or zoledronic acid, but it also makes it one of the most expensive osteoporosis treatments on the market. The monthly list price of approximately $3,200 places it in the specialty drug category for virtually every large health plan in the United States, including Kaiser Permanente.

Because specialty drugs carry high costs and because Forteo carries an FDA black-box warning about osteosarcoma risk observed in rat studies, insurers typically require physicians to demonstrate that a patient truly needs an anabolic agent before approving coverage. The FDA limits lifetime use to 24 months, reinforcing that this drug is reserved for patients at the highest end of fracture risk. According to the FDA label, Forteo is approved for postmenopausal women, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis who are at high or very high fracture risk.

Kaiser Permanente operates eight regional health plans across the United States, and formulary decisions are made at the regional level. A member in Southern California may face slightly different tier placement or criteria than a member in Colorado or Georgia, though the underlying clinical logic is consistent.

How Kaiser Permanente's Formulary System Works for Specialty Drugs

Kaiser Permanente uses a multi-tier formulary. Generic drugs sit on Tier 1 at the lowest cost sharing. Preferred brand drugs occupy Tier 2 or 3. Specialty drugs, including Forteo, typically land on Tier 4 or Tier 5, where cost sharing is either a percentage of the drug's cost (coinsurance) or a high flat copay. On many Kaiser commercial plans, the Tier 5 specialty copay can run $100, $250 per 28-day supply after prior authorization. Without authorization, the member bears full cost.

Prior authorization for specialty osteoporosis drugs is handled through Kaiser's internal pharmacy and therapeutics committee process. Your prescribing physician submits a request to Kaiser's pharmacy department, usually through the regional electronic health record. The request includes your dual-energy X-ray absorptiometry (DXA) scan results, fracture history, and documentation that first-line agents were tried or are contraindicated.

The Endocrine Society's 2019 clinical practice guideline states that "anabolic therapy should be reserved for patients with very high fracture risk, defined as recent fracture, very low T-scores (below -3.0), multiple fractures, or fractures while receiving antiresorptive therapy." [1] Kaiser's internal criteria closely mirror this language, which means your physician needs to place you squarely within that definition for the authorization to succeed.

Specific Clinical Criteria Kaiser Typically Requires for Forteo

Meeting Kaiser's prior authorization requirements is manageable when your physician prepares the request carefully. The criteria below reflect what Kaiser regions have publicly disclosed in their formulary exception guidelines as well as standard industry benchmarks for teriparatide authorization.

T-score threshold. A DXA scan showing a T-score of -2.5 or lower at the lumbar spine or hip, or a T-score of -1.0 to -2.5 in a patient who has already sustained a low-trauma fracture, is generally required. A T-score below -3.0 strengthens the case considerably.

Bisphosphonate failure or intolerance. Most Kaiser regions require documentation that the patient has tried at least one oral bisphosphonate (alendronate or risedronate are cheapest and preferred) for an adequate trial period (usually 12 months) and either experienced an on-treatment fracture, showed continued bone density decline, or developed a documented intolerance such as esophageal adverse effects, osteonecrosis of the jaw, or atypical femur fracture.

Fracture history. A vertebral or hip fracture within the past 24 months substantially increases the likelihood of approval. The FRAX 10-year probability of major osteoporotic fracture exceeding 20% or hip fracture exceeding 3% also supports the case when bisphosphonate contraindications are present.

Diagnosis specificity. Glucocorticoid-induced osteoporosis requires separate documentation: prednisone equivalent of at least 7.5 mg/day for 3 months or longer, combined with either a T-score below -1.5 or a prior fragility fracture.

The key fracture trial for teriparatide, the Fracture Prevention Trial (N=1,637 postmenopausal women with prior vertebral fractures), showed a 65% reduction in new vertebral fractures and a 53% reduction in non-vertebral fragility fractures over a median of 21 months compared with placebo (P<0.001 for vertebral fractures). [2] That magnitude of effect is part of why clinicians advocate aggressively for authorization when patients meet criteria.

How to File a Prior Authorization Request at Kaiser

Your endocrinologist, rheumatologist, or primary care physician must initiate the prior authorization. As a patient, your most effective role is to gather records before the appointment.

Bring your most recent DXA scan results (within the past 24 months), a written list of every osteoporosis medication you have tried with dates and reasons for stopping, any radiology reports documenting vertebral or peripheral fractures, and a list of current medications including corticosteroids. A FRAX score printout from sheffield.ac.uk/FRAX, while not a primary medical source, gives your physician a documented risk estimate to include in the request letter.

Kaiser's pharmacy team typically responds to prior authorization requests within 3 to 5 business days for non-urgent cases and 72 hours for urgent medical need designations. If the initial request is denied, the treating physician can submit a peer-to-peer review call with the Kaiser medical director reviewing the case. Data from the Kaiser Permanente Research Bank suggest that peer-to-peer reviews reverse initial denials in a meaningful percentage of specialty drug cases, though published regional-level numbers are not publicly available.

What Happens If Kaiser Denies Coverage for Forteo?

A denial is not the end of the road. Kaiser members in all regions have appeal rights guaranteed by state law and the Affordable Care Act. The process has three stages.

First-level internal appeal. Your physician submits a written appeal with additional clinical documentation. This appeal must be acknowledged within 30 days (or 72 hours for expedited urgent appeals). Kaiser's appeals team, which includes clinical pharmacists and physician reviewers, re-evaluates the case.

Second-level internal appeal. If the first appeal fails, a second internal review involving senior medical staff is available in most Kaiser regions.

Independent Medical Review (IMR). California members specifically have the right to an IMR through the California Department of Managed Health Care (DMHC). IMR decisions are binding on Kaiser. Other states have analogous external review processes. A 2020 DMHC report found that independent reviewers overturned insurer decisions in favor of the member in roughly 36% of specialty drug cases reviewed, which makes pursuing an IMR worthwhile when clinical need is well-documented.

During the appeals process, Eli Lilly offers the Lilly Cares Foundation Patient Assistance Program for patients who meet income criteria (generally household income at or below 400% of the federal poverty level). This program can supply Forteo at no cost while authorization is pending or after a final denial, and it is worth applying simultaneously.

Cost-Saving Options If Forteo Is Approved but Still Expensive

Even with prior authorization, specialty tier cost sharing can be steep. These options may reduce what you pay out of pocket.

Eli Lilly's Forteo Savings Card. Commercially insured patients (not Medicare or Medicaid) may use Eli Lilly's savings card to pay as little as $25 per month, subject to eligibility limits. The savings card does not work for Kaiser Medicare Advantage plans. Current details are posted at forteo.com, though availability changes periodically.

Medicare Part D considerations. Kaiser Senior Advantage plans use Medicare Part D formularies. Forteo on Part D is typically in the specialty tier with a 25 to 33% coinsurance. With the 2025 Medicare redesign capping out-of-pocket drug costs at $2,000 annually, high-cost specialty drugs like Forteo become more accessible for Medicare-eligible Kaiser members than in prior years.

Switching to abaloparatide (Tymlos). Abaloparatide, manufactured by Radius Health, has a similar mechanism to teriparatide and is FDA-approved for postmenopausal women with osteoporosis at high fracture risk. Some Kaiser regions preferentially cover Tymlos over Forteo on their specialty formulary. In the ACTIVE trial (N=2,463), abaloparatide reduced new vertebral fractures by 86% compared with placebo over 18 months (P<0.001). [3] Discuss with your physician whether Tymlos would be covered at a lower tier in your specific Kaiser plan before committing to a Forteo authorization battle.

Romosozumab (Evenity). For patients with very high fracture risk who need anabolic therapy, romosozumab is a monthly injection approved for 12 months. It was shown in the ARCH trial (N=4,093) to reduce vertebral fractures by 48% versus alendronate over 24 months. [4] Some Kaiser plans may cover it more favorably, though it carries a black-box warning for cardiovascular events and is contraindicated within 12 months of a myocardial infarction or stroke.

How Kaiser's Regional Formularies Differ: A Practical Note

Kaiser Permanente has eight distinct regional medical groups: Northern California, Southern California, Colorado, Northwest (Oregon/Washington), Mid-Atlantic, Georgia, Hawaii, and Washington. Each region operates its own pharmacy and therapeutics committee, meaning Forteo's tier placement, prior authorization criteria, and preferred alternatives are not identical across all regions.

As a general framework, members can evaluate their regional formulary status in three steps. First, log in to kp.org and manage to "Pharmacy" then "Drug Cost and Coverage." Second, search for teriparatide or Forteo to see the current tier and any noted restrictions. Third, if the drug appears with a restriction flag, download the prior authorization form specific to your region (it will be labeled with criteria) and share it with your prescribing physician before the appointment so the office can prepare documentation in advance.

The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) 2022 Clinician's Guide states: "Treatment should be initiated in postmenopausal women and men aged 50 and older presenting with a hip or vertebral fracture, those with T-scores at or below -2.5 at the femoral neck or lumbar spine, and those with low bone mass (T-scores between -1.0 and -2.5) with a 10-year probability of hip fracture at or above 3% or major osteoporosis-related fracture at or above 20%." [5] Printing this guideline section and attaching it to a prior authorization request adds weight to your physician's clinical argument.

The Clinical Case for Anabolic Therapy: Why This Fight Is Worth Having

Some patients hesitate to push for Forteo coverage because they view osteoporosis as a slow-moving condition. The fracture data say otherwise. A hip fracture in adults over 65 carries a 20 to 30% one-year mortality rate. [6] Vertebral fractures double the risk of subsequent fractures. For patients with T-scores below -3.0 and existing fractures, bisphosphonates alone may not provide adequate fracture protection, and the anabolic-first strategy recommended by the Endocrine Society produces significantly larger gains in bone mineral density than starting with antiresorptive therapy.

A 2019 head-to-head trial (DATA-Switch extension, N=94) demonstrated that patients who received teriparatide first followed by denosumab achieved substantially greater femoral neck BMD gains over four years than those who received the reverse sequence. [7] The sequence matters clinically, and Kaiser's own internists generally acknowledge this when reviewing peer-to-peer appeals that cite this data directly.

If you are a Kaiser member with a T-score below -2.5, a recent fracture, and either bisphosphonate failure or a contraindication to bisphosphonates, your physician should be prepared to make a firm, documented case for Forteo or an equivalent anabolic agent. The clinical evidence for benefit is strong, the authorization pathway exists, and the appeals process provides an additional safety net.

A straightforward clinical target for your prescribing physician: include in the prior authorization request your most recent DXA T-score, the specific date and type of any fragility fracture within the past 24 months, the name, dose, and duration of every bisphosphonate trial with the documented reason for stopping, your FRAX 10-year major fracture probability, and a direct citation to the 2022 Bone Health and Osteoporosis Foundation Clinician's Guide threshold criteria.